Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Effect of Theravex Tissue Care on Implant Stability

NCT: NCT07707388 · NOT_YET_RECRUITING

NCT IDNCT07707388
StatusNOT_YET_RECRUITING
Start Date2026-11-12
Completion2027-09-08
SponsorAin Shams University (OTHER)
First posted
Last updated

Brief Summary

The aim of this randomized clinical trial is to evaluate the clinical and radiographic outcomes of using Bone Bioactive Liquid (Theravex) compared to Xenograft and a combination therapy (Theravex + Xenograft) during immediate implant placement in the esthetic zone. When a tooth is extracted and replaced immediately with a dental implant, bone grafting is often necessary to fill the gap (jumping distance) between the implant and the surrounding bone socket to support tissue healing and maintain facial contour. Participants requiring immediate implant placement will be randomly assigned into three groups: Group 1: Immediate implant placement using Bone Bioactive Liquid (Theravex). Group 2: Immediate implant placement using Xenograft alone. Group 3: Immediate implant placement using Combination Therapy (Theravex + Xenograft). The primary outcomes will evaluate implant stability, bone dimensional changes, and soft tissue response around the implants over the follow-up period.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑